They found that miR-320a directly targets PBX3 (pre-B-cell leukemia transcription factor 3), thus suppressing the activation of the MEK/ERK MAPK pathway and, consequently, HCC cell proliferation [266]. The gene discussed is PBX3; the disease is hepatocellular carcinoma.